These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20838056)

  • 1. Trastuzumab as single agent therapy for HER2-positive metastatic breast cancer.
    Rastogi P; Davidson NE
    Onkologie; 2010; 33(8-9):420-1. PubMed ID: 20838056
    [No Abstract]   [Full Text] [Related]  

  • 2. Trastuzumab single-drug therapy after failure of cytotoxic treatment for metastatic breast cancer.
    Clemens M; Eidtmann H; Nitz U; Niederle N; du Bois A; Grischke EM; Hinke A; von Minckwitz G
    Onkologie; 2010; 33(8-9):425-30. PubMed ID: 20838057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
    Tokuda Y; Suzuki Y; Saito Y; Umemura S
    Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.
    Ferretti G; Fabi A; Felici A; Papaldo P
    J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395
    [No Abstract]   [Full Text] [Related]  

  • 5. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W; Esteva FJ
    Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 and trastuzumab: impact of a new standard agent on local control and surgery for breast cancer.
    Ziogas D; Ignatiadou E; Roukos D; Lykoudis E
    Ann Surg Oncol; 2008 Dec; 15(12):3614-5; author reply 3616. PubMed ID: 18521683
    [No Abstract]   [Full Text] [Related]  

  • 8. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 10. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant trastuzumab for HER2-positive early breast cancer.
    Palmieri FM; Myatt CV; Perez EA
    Clin J Oncol Nurs; 2010 Jun; 14(3):326-36. PubMed ID: 20529794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuing trastuzumab beyond progression.
    Jahanzeb M
    J Clin Oncol; 2009 Apr; 27(12):1935-7. PubMed ID: 19289613
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant trastuzumab for HER2-positive breast cancer.
    Spicer J; Harries M; Ellis P
    Lancet; 2005 Aug 20-26; 366(9486):634. PubMed ID: 16112298
    [No Abstract]   [Full Text] [Related]  

  • 14. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care.
    Brufsky A
    Am J Clin Oncol; 2010 Apr; 33(2):186-95. PubMed ID: 19675448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer.
    Bedard PL; Piccart-Gebhart MJ
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S157-65. PubMed ID: 19158036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
    Spector NL; Blackwell KL
    J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.
    de Munck L; Schaapveld M; Siesling S; Wesseling J; Voogd AC; Tjan-Heijnen VC; Otter R; Willemse PH
    Breast Cancer Res Treat; 2011 Aug; 129(1):229-33. PubMed ID: 21431871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
    Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.
    Ferretti G; Felici A; Papaldo P; Carlini P; Fabi A; Cognetti F
    Oncologist; 2006 May; 11(5):533; author reply 534. PubMed ID: 16720857
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.